@FierceBiotech: IPO hopeful rEVO puts off its plans for a $75M debut. Item | Follow @FierceBiotech
@JohnCFierce: Interesting to see which #biotech #IPOs do well and which flop. Congrats to $DERM. | Follow @JohnCFierce
@DamianFierce: ICYMI: $LLY's bailing on tabalumab in lupus after two Phase III misses. Release | Follow @DamianFierce
@EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. | Follow @EmilyMFierce
> Eli Lilly's ($LLY) announcement that its late-stage tabalumab failed in lupus, boosted shares of XTL Biopharmaceuticals ($XTLB), at work on its own treatment for the disease. News
> AstraZeneca ($AZN) and Clovis Oncology ($CLVS) are racing to the FDA with drugs for treatment-resistant lung cancer, angling for position in a market expected to clock in at $3 billion a year. Story
Medical Device News
@FierceMedDev: Have you checked out our 15 most promising #medtech companies yet? Report | Follow @FierceMedDev
@VarunSaxena2: Alnylam says it wants to enter larger disease areas using partnership-driven approach. News | Follow @VarunSaxena2
@EmilyWFierce: FDA cracking down on companies marketing essential oils as treatments or cures for Ebola. More from the WSJ | Follow @EmilyWFierce
> Hopkins physician creates 3-D printed hands for pediatric patients. More
> EU regulators to conduct antitrust probe of $13.4B Zimmer/Biomet deal. Story
> Glooko enables wireless smartphone access for existing blood glucose monitors. News
Pharma News
@FiercePharma: Did you miss our latest special report yesterday? Not to worry: Top 10 pharma companies by employees - 2014. Report | Follow @FiercePharma
@CarlyHFierce: Salix drops Cosmo buy, opting to talk takeover with Actavis. More | Follow @CarlyHFierce
> Ascension hospitals bar Genentech reps after cancer drug distribution switch. Story
> NICE nixes Roche's new leukemia drug Gazyvaro despite discount offer. News
> Add Arbor Pharma to your shopping list: It's on the block for $1B-plus. Article